Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment

Coronavirus disease-19 (COVID-19), caused by the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide pandemic. The disease primarily spreads through respiratory droplets and manifests with a wide range of symptoms, from mild respiratory illness to sev...

Full description

Saved in:
Bibliographic Details
Main Authors: Somayeh Arabzadeh, Sohameh Mohebbi, Zahra Faal, Neda Jalali, Kayvan Saeedfar
Format: Article
Language:English
Published: University of Mazandaran 2025-01-01
Series:Journal of Genetic Resources
Subjects:
Online Access:https://sc.journals.umz.ac.ir/article_5430_c085e75bee58d81f05c196d6666407fb.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849721583304704000
author Somayeh Arabzadeh
Sohameh Mohebbi
Zahra Faal
Neda Jalali
Kayvan Saeedfar
author_facet Somayeh Arabzadeh
Sohameh Mohebbi
Zahra Faal
Neda Jalali
Kayvan Saeedfar
author_sort Somayeh Arabzadeh
collection DOAJ
description Coronavirus disease-19 (COVID-19), caused by the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide pandemic. The disease primarily spreads through respiratory droplets and manifests with a wide range of symptoms, from mild respiratory illness to severe pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. The virus manipulates the host cell cycle to create a favorable environment for its replication and propagation. One of the key regulators of the cell cycle is cyclin-D, a protein essential for the G1 to S phase transition in the cell cycle, and P53, a critical tumor suppressor and regulator of cell cycle arrest and apoptosis. Therapeutic strategies, including antiviral drugs like Remdesivir, have shown varying efficacy in managing symptoms and reducing mortality. This study obtained blood samples from 30 COVID-19 patients before and after Remdesivir treatment and 20 healthy individuals. RNA was isolated, and cDNA was subsequently synthesized. The expression levels of the p53 and cyclin-D genes were then assessed using Real-time PCR. The results demonstrate that cyclin-D expression increased 9 times in COVID-19 patients compared to the control group (P<0.001), which remained unaffected by Remdesivir treatment. Conversely, p53 gene expression was reduced by 50% in the patient group compared to the control group (P<0.05). Treatment with Remdesivir increased P53 gene expression twofold compared to the control group (P<0.001). Furthermore, P53 gene expression positively correlated with CRP (C Reactive Protein) levels in both the control and patient groups (P<0.01). The study's findings indicate that certain symptoms of COVID-19 may be linked to the virus's impact on crucial cell cycle genes, such as cyclin-D and p53. Remdesivir, by reducing inflammation and inhibiting viral replication, can help restore normal expression levels of these genes. This may support the therapeutic benefits of using Remdesivir in treating COVID-19.
format Article
id doaj-art-e1a0d3228286435c98f451d48a1786b6
institution DOAJ
issn 2423-4257
2588-2589
language English
publishDate 2025-01-01
publisher University of Mazandaran
record_format Article
series Journal of Genetic Resources
spelling doaj-art-e1a0d3228286435c98f451d48a1786b62025-08-20T03:11:38ZengUniversity of MazandaranJournal of Genetic Resources2423-42572588-25892025-01-01111213010.22080/jgr.2025.28440.14215430Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir TreatmentSomayeh Arabzadeh0Sohameh Mohebbi1Zahra Faal2Neda Jalali3Kayvan Saeedfar4Department of Biology, Faculty of Basic science, Ale Taha institute of higher education, Tehran, IranDepartment of Biology, Faculty of Basic Science, Ale Taha Institute of Higher Education, Tehran, Iran.Department of Biology, Faculty of Basic Science, Ale Taha Institute of Higher Education, Tehran, Iran.Department of Biology, Faculty of Basic Science, Ale Taha Institute of Higher Education, Tehran, Iran.Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IranCoronavirus disease-19 (COVID-19), caused by the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide pandemic. The disease primarily spreads through respiratory droplets and manifests with a wide range of symptoms, from mild respiratory illness to severe pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. The virus manipulates the host cell cycle to create a favorable environment for its replication and propagation. One of the key regulators of the cell cycle is cyclin-D, a protein essential for the G1 to S phase transition in the cell cycle, and P53, a critical tumor suppressor and regulator of cell cycle arrest and apoptosis. Therapeutic strategies, including antiviral drugs like Remdesivir, have shown varying efficacy in managing symptoms and reducing mortality. This study obtained blood samples from 30 COVID-19 patients before and after Remdesivir treatment and 20 healthy individuals. RNA was isolated, and cDNA was subsequently synthesized. The expression levels of the p53 and cyclin-D genes were then assessed using Real-time PCR. The results demonstrate that cyclin-D expression increased 9 times in COVID-19 patients compared to the control group (P<0.001), which remained unaffected by Remdesivir treatment. Conversely, p53 gene expression was reduced by 50% in the patient group compared to the control group (P<0.05). Treatment with Remdesivir increased P53 gene expression twofold compared to the control group (P<0.001). Furthermore, P53 gene expression positively correlated with CRP (C Reactive Protein) levels in both the control and patient groups (P<0.01). The study's findings indicate that certain symptoms of COVID-19 may be linked to the virus's impact on crucial cell cycle genes, such as cyclin-D and p53. Remdesivir, by reducing inflammation and inhibiting viral replication, can help restore normal expression levels of these genes. This may support the therapeutic benefits of using Remdesivir in treating COVID-19.https://sc.journals.umz.ac.ir/article_5430_c085e75bee58d81f05c196d6666407fb.pdfcell cyclecovid-19cyclin-dp53remdesivir
spellingShingle Somayeh Arabzadeh
Sohameh Mohebbi
Zahra Faal
Neda Jalali
Kayvan Saeedfar
Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment
Journal of Genetic Resources
cell cycle
covid-19
cyclin-d
p53
remdesivir
title Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment
title_full Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment
title_fullStr Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment
title_full_unstemmed Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment
title_short Assessment of Alterations in the Expression of P53 and Cyclin-D Genes in COVID-19 Patients Before and After Remdesivir Treatment
title_sort assessment of alterations in the expression of p53 and cyclin d genes in covid 19 patients before and after remdesivir treatment
topic cell cycle
covid-19
cyclin-d
p53
remdesivir
url https://sc.journals.umz.ac.ir/article_5430_c085e75bee58d81f05c196d6666407fb.pdf
work_keys_str_mv AT somayeharabzadeh assessmentofalterationsintheexpressionofp53andcyclindgenesincovid19patientsbeforeandafterremdesivirtreatment
AT sohamehmohebbi assessmentofalterationsintheexpressionofp53andcyclindgenesincovid19patientsbeforeandafterremdesivirtreatment
AT zahrafaal assessmentofalterationsintheexpressionofp53andcyclindgenesincovid19patientsbeforeandafterremdesivirtreatment
AT nedajalali assessmentofalterationsintheexpressionofp53andcyclindgenesincovid19patientsbeforeandafterremdesivirtreatment
AT kayvansaeedfar assessmentofalterationsintheexpressionofp53andcyclindgenesincovid19patientsbeforeandafterremdesivirtreatment